Bezafibrate and fenofibrate in type II diabetics with hyperlipoproteinaemia.

A double-blind study was carried out in 64 Type II diabetic patients, controlled with diet therapy and sulphonylureas (glibenclamide or chlorpropamide), who had associated hyperlipoproteinaemia which could not be normalized during a run-in period of 2 months by hygiene and dietary measures alone. The patients were allocated at random into 4 groups and each group was treated over 4 months with bezafibrate (600 mg/day) or fenofibrate (300 mg/day) in addition to their glibenclamide (5 to 15 mg/day) or chlorpropamide (250 to 500 mg/day) therapy plus diet. The results of monthly laboratory investigations showed that both hypolipaemic agents produced significant reductions in serum triglycerides, total cholesterol and LDL cholesterol and an increase in HDL cholesterol. There was a significantly greater increase in HDL cholesterol in patients treated with bezafibrate and glibenclamide, particularly in women, and greater control of blood glucose in those on bezafibrate. Both hypolipaemic drugs were well tolerated. Slight increases were recorded in serum transaminases in fenofibrate patients and in bleeding time in bezafibrate patients. It is concluded that, because of its greater effect on blood glucose and HDL cholesterol, the combination of bezafibrate with glibenclamide would appear to be the best of the regimens studied for the treatment of non-insulin-dependent diabetics with associated hyperlipoproteinaemia.

Xantomas diseminados. / Disseminated xanthomas

Presentacion de un caso de xantomas diseminados en una mujer de edad mediana. No han sido detectados ni diabetes, ni alteraciones del lipidograma, ni lesiones sistemicas, ni oseas. Se llama la atencion sobre el rapido desarrollo expansivo de algunos de los xantomas que, por su gran volumen, toman caracter pendulo. La paciente tiene como unico antecedente patologico sugestivo una colecistectomia efectuada 17 anos antes por enfermedad vesicular cuya exacta naturaleza desconece. El xantoma diseminado es una variedad de xantoma normo-lipemico que puede tambien ubicarse dentro de las histiocitosis X, como una varianta del Hand-Schuller-Christian, segun Thannhauser

Xantomas diseminados. / Disseminated xanthomas

Presentacion de un caso de xantomas diseminados en una mujer de edad mediana. No han sido detectados ni diabetes, ni alteraciones del lipidograma, ni lesiones sistemicas, ni oseas. Se llama la atencion sobre el rapido desarrollo expansivo de algunos de los xantomas que, por su gran volumen, toman caracter pendulo. La paciente tiene como unico antecedente patologico sugestivo una colecistectomia efectuada 17 anos antes por enfermedad vesicular cuya exacta naturaleza desconece. El xantoma diseminado es una variedad de xantoma normo-lipemico que puede tambien ubicarse dentro de las histiocitosis X, como una varianta del Hand-Schuller-Christian, segun Thannhauser

Comparacion de probucol y clofibrate. Estudio doble ciego cruzado. / Comparison between probucol and clofibrate. A double-blind cross-over study

Se llevo al cabo un estudio doble ciego cruzado de 16 pacientes con hipercolesterolemia primaria, de ambos sexos, edad media 45.4 anos, para comparar la eficacia de probucol y clofibrate. Se formaron dos grupos de 8 pacientes seleccionados al azar. Uno recibio probucol 4 comprimidos diarios de 250 mg y placebo; el otro 4 capsulas diarias de clofibrate 500 mg y placebo, en ambos grupos por 60 dias. Despues de un periodo de 5 meses sin tratamiento, al grupo que recibio probucol + placebo y alque se le habia dado clofibrate + placebo se le dio probucol + placebo, a las mismas dosis por otros 60 dias. Los resultados mostraron que probucol es mas efical que clofibrate para bajar los niveles de colesterol; que difiene poco o clofibrate en la produccion de efectos secundarios y que es bien tolerado

Randomised trial of pentoxifylline versus acetylsalicylic acid plus dipyridamole in preventing transient ischaemic attacks.

In a multicentre trial to compare the ability of a combination of acetylsalicylic acid and dipyridamole (1050 mg + 150 mg/day, group A) to prevent recurrence of transient ischaemic attacks (TIA) with that of pentoxifylline (1200 mg/day, group B), 36 patients received the combination and 30 pentoxifylline. There was no statistically significant difference between the groups as regards age, sex, blood pressure, site of origin of TIA, and incidence of other risk factors. The incidence of recurrent TIAs during 1 year of follow-up was 28% in group A and 10% in group B; this difference was significant (p less than 0.05). The incidence of permanent strokes was similar in the two groups but distinctly lower (4.5%) than that usually reported after untreated TIA.

A randomized clinical trial of pentoxifylline and antiaggregants in recent transient ischemic attacks (TIA). A one year follow-up.

A multicenter comparative trial was conducted in patients with transient ischemic attacks (TIA) to study the preventive capacity of a combination of acetylsalicylic acid and dipyridamol (1,050 mg + 150 mg/day - group A) and of pentoxifylline (1,200 mg/day - group P) in the reduction of morbidity rates. Sixty-six patients, 36 on A and 30 on P, were evaluated. There was no statistically significant difference between both groups as regards age, sex, blood pressure, localisation of TIA and incidence of risk factors. Incidence of new ischemic events during a one year follow up period in the A-group was 28% compared to 10% in the P-group, this difference being statistically significant in favour of P (p less than 0.05). Stroke incidence was similar in both groups but distinctly lower (4.5%) than the natural frequency in TIA.